Biogen Inc. (BIIB) Stock Analysis — Fair Value, Risk & Moat Rating
NMS · Healthcare · Drug Manufacturers - General
Is Biogen Inc. a safe investment right now?
Biogen Inc.'s Altman Z-Score of 3.24 places it in the safe zone. Our fair value estimate is $211.78 (Buy Zone). Moat rating: 3.0/5 stars.
Could Biogen Inc. go bankrupt? Altman Z-Score analysis
Z-Score of 3.24 is above 3.0, indicating the company is financially healthy by this metric.
- Below 1.8 — Distress Zone (high bankruptcy risk)
- 1.8 to 3.0 — Gray Zone (elevated uncertainty)
- Above 3.0 — Safe Zone (financially healthy)
What drives BIIB's Z-Score?
| Component | Formula | Value | Weight | Contribution |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.1911 | 1.2 | 0.23 |
| B · Retained Earnings / Total Assets | RE / TA | 0.6981 | 1.4 | 0.98 |
| C · EBIT / Total Assets | EBIT / TA | 0.062 | 3.3 | 0.2 |
| D · Market Cap / Total Liabilities | MCap / TL | 2.4944 | 0.6 | 1.5 |
| E · Revenue / Total Assets | Rev / TA | 0.336 | 1.0 | 0.34 |
How has BIIB's financial health changed over time?
| Year | Z-Score | Zone |
|---|---|---|
| 2022 | 3.69 | Safe |
| 2023 | 3.02 | Safe |
| 2024 | 3.12 | Safe |
| 2025 | 3.24 | Safe |
Source: Calculated from BIIB's latest 10-K filing on SEC EDGAR.
What is Biogen Inc. actually worth?
How we calculated this
| Input | Value | Source |
|---|---|---|
| Predicted EPS (α) | $11.51 | Proprietary blend of reported actuals + analyst consensus, weighted by α |
| Last Year EPS | $8.79 | Annual report (SEC EDGAR) |
| Analyst Consensus EPS (This Year) | $15.58 | 30 analysts consensus |
| Trailing P/E | 21.6x | Current market pricing |
| Fair P/E (β discount) | 18.4x | Trailing PE adjusted by value discount factor β, hard-capped |
| Earnings Trend (γ) | Accelerating | Directional signal: predicted vs trailing EPS |
Wall Street Reference: Analyst consensus target price is $209.36 (30 analysts). This is shown for reference only and is not used in our valuation model.
Source: Earnings data from SEC EDGAR filings. Market data via Yahoo Finance.
Does Biogen Inc. have a durable competitive advantage?
Moat rating: 3.0/5.
What makes up BIIB's moat score?
ROIC Stability
ROIC variability over the past decade. Score: 3/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 3/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 3/5.
How stable is BIIB's return on invested capital?
| Year | ROIC | Trend |
|---|---|---|
| 2022 | 19.5% | — |
| 2023 | 7.1% | Declining |
| 2024 | 9.4% | Rising |
| 2025 | 7.4% | Declining |
Source: ROIC calculated from SEC EDGAR filings.
Is Biogen Inc.'s dividend safe?
Biogen Inc.'s key financial metrics
| Metric | Latest | 1Y Ago | 3Y Ago | Trend |
|---|---|---|---|---|
| Revenue | $9.9B | $9.7B | $10.2B | Stable |
| Net Income | $1.3B | $1.6B | $3.0B | Declining |
| Free Cash Flow | $2.0B | $2.5B | $1.1B | Rising |
| Gross Margin | 75.7% | 76.1% | 77.6% | Stable |
Recent events that affect our BIIB analysis
BIIB earnings report scheduled
Upcoming report. Consensus EPS estimate: $3.01. Revenue estimate: $2.26B. Our current Fair Value: $211.78 — a significant beat or miss could shift this estimate.
BIIB analyst consensus: 53% bullish (19 of 36 analysts)
3 Strong Buy, 16 Buy, 16 Hold, 1 Sell, 0 Strong Sell. Consensus target: $209.36 (10.1% upside). Compare with our independent Fair Value: $211.78.
BIIB filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BIIB filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BIIB filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BIIB filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BIIB beat EPS estimates by 23.2%
Reported EPS: $1.99 vs estimate $1.62. Earnings strength supports our Fair Value of $211.78 (11.4% above current price).
BIIB filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
BIIB filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BIIB filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BIIB beat EPS estimates by 23.9%
Reported EPS: $4.81 vs estimate $3.88. Earnings strength supports our Fair Value of $211.78 (11.4% above current price).
BIIB filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
BIIB filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BIIB filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BIIB beat EPS estimates by 41.0%
Reported EPS: $5.47 vs estimate $3.88. Earnings strength supports our Fair Value of $211.78 (11.4% above current price).
BIIB filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BIIB filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
BIIB filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BIIB filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BIIB filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BIIB beat EPS estimates by 2.4%
Reported EPS: $3.02 vs estimate $2.95. Earnings strength supports our Fair Value of $211.78 (11.4% above current price).
BIIB filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
BIIB filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BIIB beat EPS estimates by 2.3%
Reported EPS: $3.44 vs estimate $3.36. Earnings strength supports our Fair Value of $211.78 (11.4% above current price).
BIIB filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
BIIB filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
BIIB filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
Common questions about Biogen Inc.
What is Biogen Inc. stock price today?
Biogen Inc. (BIIB) stock price is $190.07 as of the latest market close, traded on the NASDAQ exchange.
What does Biogen Inc. do?
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. It provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.
What is Biogen Inc. market cap?
Biogen Inc. has a market capitalization of $27.89B, classifying it as a large-cap stock in the Healthcare sector.
What sector and industry is BIIB in?
Biogen Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. It trades on the NASDAQ under the ticker symbol BIIB.
Is BIIB stock overvalued or undervalued?
Based on our valuation model, Biogen Inc. trades 10.2% below our fair value estimate — potentially undervalued.
- FairValueLabs Fair Value: $211.78
- Current Price: $190.07
- Valuation Zone: Buy Zone
What is BIIB stock forecast and analyst target price?
Based on 30 Wall Street analysts, the consensus price target for Biogen Inc. is $209.36, implying upside of 10.1% from the current price.
- Analyst High Target: $275.00
- Analyst Low Target: $150.00
Note: Analyst targets are shown for reference and are not used in our valuation model.
Is Biogen Inc. revenue and earnings growing?
Here are the analyst consensus growth estimates for Biogen Inc.:
- Revenue growth (current year est.): -4.2%
- EPS growth (current year est.): 2.0%
- Revenue growth (next year est.): -1.4%
- EPS growth (next year est.): 1.6%
What are Biogen Inc.'s key financial metrics?
| Metric | Latest | Trend |
|---|---|---|
| Revenue | $9.9B | Stable |
| Net Income | $1.3B | Declining |
| Free Cash Flow | $2.0B | Rising |
| Gross Margin | 75.7% | Stable |
What is BIIB's P/E ratio?
The price-to-earnings ratio measures how much investors pay per dollar of earnings:
- Trailing P/E (last 12 months): 21.6x
- Forward P/E (next 12 months est.): 11.9x
- FairValueLabs Fair P/E: 18.4x
How volatile is BIIB stock?
Biogen Inc. has a beta of 0.16, meaning it is less volatile than the broader market. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.
How much cash and debt does Biogen Inc. have?
Biogen Inc.'s balance sheet shows:
- Total Cash: $3.82B
- Total Debt: $6.66B
- Net Cash Position: $-2.84B
A positive net cash position means the company holds more cash than debt, reducing financial risk.
What is Biogen Inc.'s free cash flow?
Biogen Inc. generated $1.98B in trailing twelve-month free cash flow (from $2.20B in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.
Does Biogen Inc. pay a dividend?
Biogen Inc. does not currently pay a regular dividend to shareholders. The company may be reinvesting all profits back into growth, or it may have suspended its dividend.
Is Biogen Inc. at risk of going bankrupt?
Biogen Inc.'s Altman Z-Score is 3.24, placing it in the safe zone (above 3.0) — bankruptcy risk is low. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.
Does Biogen Inc. have a durable competitive advantage?
Biogen Inc. scores 3.0/5 stars (Narrow moat) in our moat analysis:
- ROIC Stability: 3/5
- Gross Margin Trend: 3/5
- Switching Costs: 3/5
A score above 3.5 suggests meaningful pricing power and a defensible market position.
What is BIIB's return on equity (ROE)?
Biogen Inc.'s return on equity is 7.4%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.
How do I buy BIIB stock?
BIIB shares can be purchased through any brokerage account that provides access to the NASDAQ. Common steps:
- Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
- Search for ticker symbol BIIB
- Place a market or limit order for your desired number of shares
This is not investment advice. Always do your own research before buying any stock.
Is BIIB a value stock or speculative?
FairValueLabs classifies Biogen Inc. as Value Investment. It exhibits consistent profitability, reasonable valuation, and financial stability — characteristics of a traditional value investment.
Who is the CEO of Biogen Inc.?
The current CEO of Biogen Inc. is Mr. Christopher A. Viehbacher.
What is BIIB's earnings per share (EPS)?
Earnings per share measures the company's profit allocated to each outstanding share:
- Trailing EPS (last 12 months): $8.78
- Forward EPS (next 12 months est.): $15.94
- Analyst consensus EPS (this year): $15.58
- Analyst consensus EPS (next year): $15.83
Other Healthcare companies analyzed by FairValueLabs
FairValueLabs Disclaimer
All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
Last updated: Apr 22, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.
BIIB analysis methodology: How we calculate fair value, Z-Scores, and moat ratings